Erasca, Inc., a clinical-stage precision oncology company, reported a net loss of $124.5 million for the year ended December 31, 2025, compared to a net loss of $161.7 million for the previous year. The company, focused on developing therapies for RAS/MAPK pathway-driven cancers, has not generated any revenue since its inception and does not anticipate product sales in the near future. Research and development expenses totaled $92.9 million in 2025, a decrease from $115.4 million in 2024, primarily due to reduced clinical trial expenses, outsourced services, personnel costs, and facilities-related expenses. In-process research and development expenses decreased to $9.5 million from $22.5 million, reflecting milestone payments related to license agreements with Guangzhou Joyo Pharmatech Co., Ltd. (Joyo) and Medshine Discovery Inc. (Medshine).

General and administrative expenses also decreased to $38.6 million in 2025 from $41.7 million in 2024, mainly due to lower legal fees and insurance costs. Other income, net, was $16.4 million, a slight decrease from $17.9 million in the prior year, primarily due to lower interest income. The company's cash, cash equivalents, and marketable securities totaled $341.8 million as of December 31, 2025.

Strategic developments included the in-licensing of a RAS-targeting franchise in May 2024, consisting of ERAS-0015 and ERAS-4001, both now in clinical trials. In March 2026, Erasca exercised its option to expand its territory under the Joyo License Agreement to include mainland China, Hong Kong and Macau, and made the corresponding $150.0 million payment. The company also terminated its exclusive license agreement with Novartis for naporafenib, effective June 3, 2026, to prioritize its RAS-targeting franchise. As of February 28, 2026, Erasca had 103 full-time employees, with 70 engaged in research and development activities.

Key operational developments included the clearance of Investigational New Drug (IND) applications for ERAS-0015 and ERAS-4001 by the FDA in May 2025. Dose escalation in the ongoing AURORAS-1 Phase 1 trial for ERAS-0015 was advancing faster than anticipated, with ongoing confirmed and unconfirmed responses observed in multiple patients. The company anticipates Phase 1 monotherapy data readouts from the AURORAS-1 and JYP0015M101 trials in the first half of 2026, and from the BOREALIS-1 trial for ERAS-4001 in the second half of 2026.

Looking ahead, Erasca anticipates initiating monotherapy expansion cohorts and combination dose escalation cohorts as part of the AURORAS-1 trial in the second half of 2026, with associated data readouts planned for 2027. Based on its current operating plan, the company believes its existing financial resources, combined with the net proceeds from a January 2026 public offering, will be sufficient to fund operations into the second half of 2028. The company remains focused on advancing its RAS/MAPK pathway-focused pipeline and evaluating opportunities to accelerate development timelines through collaborations.

About Erasca, Inc.

Erasca is a clinical-stage precision oncology company focused on developing therapies targeting the RAS/MAPK pathway, a key driver in many cancers. Its pipeline includes small and large molecule therapeutics, such as pan-RAF, RAS, and EGFR inhibitors, aimed at treating high unmet medical needs across diverse tumor types. The company emphasizes combination regimens to shut down cancer signaling pathways and improve patient outcomes.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.